Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC.24: Zilbesiran in Patients With Hypertension: KARDIA-2
Author(s): Akshay S Desai Added: 1 week ago
ACC.24 — We are joined onsite by investigator, Dr Akshay Desai (Brigham and Women's Hospital, US) to discuss the findings from the KARDIA-2 randomized clinical trial (NCT05103332).KARDIA-2 is a double-blind, placebo-controlled multicenter study aiming to evaluate the effects of zilebesiran, an RNA interference agent, on the systolic and diastolic blood pressure of hypertensive patients not… View more

Prevention & Chronic Conditions
CardioNerds @AHA23: KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension
Author(s): George L Bakris , Sukriti Banthiya Added: 5 months ago
AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035).This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients… View more

Prevention & Chronic Conditions
ACC 24 Late-Breaker Discussion: The AEGIS-II Trial
Author(s): Harriette Van Spall , Michael C Gibson Added: 1 week ago
ACC 2024 — Late-breaker host, Dr Harriette Van Spall and Principal Investigator, Dr C Michael Gibson discuss the AEGIS-II trial (CSL Behring) (NCT03473223).This phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study investigated the efficacy and safety of an apolipoprotein A-I (apoA-I), CSL112 in patients with acute coronary syndrome (ACS). Investigators enrolled… View more

Prevention & Chronic Conditions

MI/ACS
AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Author(s): Mandeep Mehra , Christian Inchaustegui Added: 5 months ago
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs. View more

Vascular Disease and Surgery

Heart Failure
AHA 2023 Late-Breaking Science Lineup Revealed
Added: 6 months ago Source:  AHA, Jordan Rance
The American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals. Among the event’s highlights are eight late-breaking trial sessions, as listed below. Watch our coverage of… View more
CardioNerds @AHA23: AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF
Author(s): Naima Maqsood , Christian Ruff Added: 5 months ago
AHA 23 - Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews Dr Christian Ruff (Brigham and Women's Hospital, US) on the late-breaking findings from the AZALEA-TIMI 71 randomized trial (Anthos Theraputics, Inc).AZALEA-TIMI 71 aimed to evaluate the bleeding profile of abelacimab as compared to rivaroxaban in patients with atrial fibrillation who are at moderate to… View more

Anticoagulation

Electrophysiology & Arrhythmia
Weight Loss Medications: What You Need to Know in 2024
Author(s): Harold Bays Added: 1 week ago
ACC.24 — Dr Harold E Bays, Science Officer for the Obesity Medicine Association, a member of the Board of Trustees of the Obesity Medicine Association, and a member of the Board of Directors of the American Society of Preventive Cardiology, joins us to highlight key information regarding weight loss medications in 2024.Support: This is an independent interview conducted by Radcliffe Cardiology… View more

Prevention & Chronic Conditions
Chelation Therapy in Post-MI Pts with Diabetes: TACT2
Author(s): Gervasio L Lamas Added: 1 week ago
ACC 24 - In this video, Dr Gervasio L Lamas (Mount Sinai Medical Center, US) joins us onsite to discuss the findings from the TACT2 study of chelation therapy in post-myocardial infarction patients with diabetes (NCT02733185).The Trial to Assess Chelation Therapy 2 (TACT2) study is a randomized, double blind factorial clinical trial, aiming to determine if chelation-based strategy increases the… View more

Prevention & Chronic Conditions

MI/ACS
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD
Author(s): Brian Bergmark Added: 1 week ago
ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).This multicenter, randomized, double-blind study… View more

Prevention & Chronic Conditions
ACC.24: Late-Breaking Science Video Collection
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 week ago
Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA)… View more

Heart Failure

MI/ACS